Hansoh Pharmaceutical Group Company Limited Stock
Equities
3692
KYG549581067
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.60 HKD | -1.06% |
|
-7.08% | -6.87% |
| 05-14 | Hansoh Pharma Gets China Nod for Trial of Tumor Drug | MT |
| 05-13 | Hansoh pharmaceutical says HS-10541 tablets obtain clinical trial approval from China's NMPA | RE |
| Capitalization | 179B 206B 26.28B 22.67B 20.77B 19.62B 36.18B 2,545B 37.09B 247B 96.38B 1,198B 98.63B 96.53B 4,183B | P/E ratio 2026 * |
30x | P/E ratio 2027 * | 27.2x |
|---|---|---|---|---|---|
| Enterprise value | 144B 166B 21.19B 18.27B 16.74B 15.82B 29.16B 2,051B 29.9B 199B 77.69B 966B 79.51B 77.81B 3,372B | EV / Sales 2026 * |
8.51x | EV / Sales 2027 * | 7.48x |
| Free-Float |
20.45% | Yield 2026 * |
1.2% | Yield 2027 * | 1.3% |
| 1 day | -1.06% | ||
| 1 week | -7.08% | ||
| Current month | -9.43% | ||
| 1 month | -15.79% | ||
| 3 months | -8.55% | ||
| 6 months | -13.80% | ||
| Current year | -6.87% |
| 1 week | 33.2 |  | 36.74 |
| 1 month | 33.2 | | 40.28 |
| Current year | 30.42 | | 44.22 |
| 1 year | 24.45 | | 44.22 |
| 3 years | 9.41 | | 44.22 |
| 5 years | 9.41 | | 44.22 |
| 10 years | 9.41 | | 46.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Hui Juan Zhong
CEO | Chief Executive Officer | 65 | 02/12/2015 |
Min Hu
DFI | Director of Finance/CFO | 49 | 01/09/2019 |
Shan Jiang
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Hui Juan Zhong
CHM | Chairman | 65 | 02/12/2015 |
Ai Feng Lyu
BRD | Director/Board Member | 49 | 11/03/2016 |
Yu An Sun
BRD | Director/Board Member | 39 | 02/12/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.06% | -7.08% | +35.21% | +155.71% | 26.28B | |
| +3.37% | +3.19% | +35.27% | +130.89% | 911B | |
| +0.47% | +2.56% | +50.83% | +44.74% | 554B | |
| +2.08% | +2.84% | +15.10% | +47.31% | 378B | |
| +1.25% | +0.40% | +24.15% | +11.99% | 333B | |
| +0.01% | +0.96% | +33.40% | +15.47% | 288B | |
| +0.09% | +2.24% | +28.01% | +30.89% | 287B | |
| +1.49% | +1.66% | +47.92% | -1.08% | 282B | |
| -0.17% | -4.03% | -37.05% | -51.32% | 198B | |
| +1.96% | -1.65% | +19.90% | +48.04% | 179B | |
| Average | +0.16% | +0.56% | +25.28% | +43.26% | 343.57B | |
| Weighted average by Cap. | +0.19% | +2.06% | +29.80% | +52.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.95B 19.49B 2.49B 2.15B 1.97B 1.86B 3.42B 241B 3.51B 23.43B 9.12B 113B 9.34B 9.14B 396B | 18.59B 21.38B 2.73B 2.35B 2.16B 2.04B 3.76B 264B 3.85B 25.7B 10.01B 124B 10.24B 10.03B 434B |
| Net income | 5.9B 6.79B 866M 747M 684M 647M 1.19B 83.86B 1.22B 8.16B 3.18B 39.48B 3.25B 3.18B 138B | 6.52B 7.5B 957M 825M 756M 714M 1.32B 92.63B 1.35B 9.01B 3.51B 43.61B 3.59B 3.51B 152B |
| Net Debt | -34.72B -39.93B -5.1B -4.4B -4.03B -3.81B -7.02B -493B -7.19B -47.99B -18.69B -232B -19.13B -18.72B -811B | -40.03B -46.03B -5.88B -5.07B -4.64B -4.39B -8.09B -569B -8.29B -55.33B -21.55B -268B -22.05B -21.58B -935B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/26 | 33.60 $ | -1.06% | 6,892,362 |
| 19/05/26 | 33.96 $ | -0.59% | 12,893,810 |
| 18/05/26 | 34.16 $ | -2.84% | 7,184,243 |
| 15/05/26 | 35.16 $ | -1.51% | 9,562,840 |
| 14/05/26 | 35.70 $ | -1.27% | 8,612,431 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 3692 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition